Bone Mineral Density in Women With Major Depression
Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Nov 3, 1999
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
Osteoporosis is a condition that is underdiagnosed and undertreated, and often goes unnoticed until a fragility fracture occurs after many years of progressive loss of bone quality. Risk factors for osteoporosis include glucocorticoid excess and a pro-inflammatory state, both of which we and others have observed in a substantial proportion of patients with Major Depressive Disorder.
We have found statistically and clinically significant reductions in bone mineral density (BMD) in a group of 24 depressed but otherwise healthy pre-menopausal women, as compared to 24 healthy, closely matched ...
Gender
ALL
Eligibility criteria
- • -
- INCLUSION CRITERIA:
- • A history of current or past major depression of at least four months duration, or a history of two or more brief depressive episodes will be the primary criterion for inclusion.
- • Patients with Bipolar Disorder will be eligible if they meet the depressive episode criterion.
- • No specific inclusion criteria are set for normal volunteers.
- EXCLUSION CRITERIA:
- DEPRESSED SUBJECTS:
- • Pregnant women will not be eligible to participate.
- • Known medical causes of osteoporosis, other than depression.
- • Current or past history of eating disorders, or schizophrenia, as per DSM-IV.
- • Chronic use of oral or parenteral steroids (daily use for 3 months or longer).
- HEALTHY SUBJECTS:
- • Pregnant women will not be eligible to participate.
- • Known medical causes of osteoporosis.
- • Any history of DSM-IV diagnosis, including depression, eating disorders, and alcohol or drug abuse.
- • History or current evidence of any significant clinical or laboratory abnormalities.
About National Institute Of Mental Health (Nimh)
The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials